Inflammation and immune activation markers associated with end-organ diseases like atherosclerosis are higher in treatment-suppressed HIV patients than in non-HIV population. No therapies have been developed to effectively target these mediators. A decrease of immune activation markers after raltegravir intensification and anti-inflammatory properties of the angiotensin receptor antagonist losartan have been reported. The objective of this clinical trial was to investigate the effect of switching to raltegravir and/or adding losartan on the inflammatory/immune-activation mediators in treated HIV patients
48 chronic HIV patients successfully treated with 2 NRTI and 1 NNRTI or PI during at least 48w were randomized to: continue the same ART (n=12), switch NNRTI/PI to raltegravir (n=12), add losartan (n=12) or switch NNRTI/PI to raltegravir and add losartan (n=12) for 48w. Markers of T CD4 and CD8 lymphocytes activation (HLADR+38+) and senescence (CD28-CD57+), monocyte activation (CD14+, CD16+) and inflammation (hsCRP, TNF-alpha, D-dimer and IL-6) were determined at baseline and at w48 and compared between groups.
Median age was 41 years. The median (IQR) time since diagnosis was 8 (5-11) years and patients were on successful ART for a median (IQR) 5 (3-10) years. Median (IQR) nadir, baseline CD4 count and CD4/CD8 ratio was 307 (221-390), 723 (571-927) c/mm3 and 0,93 (0,6-1,2), respectively. Patients who switched to raltegravir showed a higher decrease in all activated [CD4+38+HLADR+ -1,3 vs -0,6 (p=0.033); CD8+38+HLADR+ -1.6 vs 1.3 (p=0.02)] and senescent [CD4+28-57+ -0.3 vs 0.26 (p=0.04); CD8+28-57+ -6.1 vs 3.8 (p=0.002)] T lymphocyte populations than those who did not change ART. CD4/CD8 ratio increased a median of 0.35 in patients in the raltegravir group vs 0.03 in patients not taking raltegravir (p=0.002). No changes were observed in patients allocated to losartan. Differences between groups in monocyte subpopulations or inflammation markers were not observed.
Switching a NNRT/PI containing regimen to raltegravir significantly improved immune system as measured by a decrease in activated and senescent T lymphocyte subpopulations and an increase in CD4/CD8 ratio in successfully treated HIV patients. Conversely, adding losartan did not have any impact on inflammation or T cell/monocyte activation or senescence.